Wave's DMD drug remains on track in 48-week data ahead of FDA push next year
As it gears up to submit an approval application next year, Wave Life Sciences has presented fresh phase 2 data to show its Duchenne muscular dystrophy therapy is up to the task.
As it gears up to submit an approval application next year, Wave Life Sciences has presented fresh phase 2 data to show its Duchenne muscular dystrophy therapy is up to the task.
